Table 2 Outcomes by TcellinfGEP Status
Low TcellinfGEP (< 1st Tertile) | Non-Low TcellinfGEP (≥ 1st Tertile) | |||
|---|---|---|---|---|
Pembrolizumab (n = 52) | Chemotherapy (n = 59) | Pembrolizumab (n = 125) | Chemotherapy (n = 97) | |
Best overall response (95% CI), % | 0.0 (0.0‒6.8) | 8.5 (2.8‒18.7) | 15.2 (9.4‒22.7) | 13.4 (7.3‒21.8) |
Progression-free survival | ||||
Median (95% CI), mo | 1.9 (1.6‒2.0) | 3.1 (2.2‒4.3) | 2.1 (2.1‒3.4) | 3.6 (2.3‒4.6) |
Hazard ratio (95% CI) | 3.63 (2.31‒5.70) | 1.40 (1.02‒1.93) | ||
Overall survival | ||||
Median (95% CI), mo | 5.6 (4.2‒7.0) | 11.5 (7.1‒15.2) | 12.7 (9.9‒15.5) | 11.1 (7.3‒13.7) |
Hazard ratio (95% CI) | 1.72 (1.15‒2.55) | 0.77 (0.58‒1.04) | ||
